CA2342634C - Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative - Google Patents
Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative Download PDFInfo
- Publication number
- CA2342634C CA2342634C CA002342634A CA2342634A CA2342634C CA 2342634 C CA2342634 C CA 2342634C CA 002342634 A CA002342634 A CA 002342634A CA 2342634 A CA2342634 A CA 2342634A CA 2342634 C CA2342634 C CA 2342634C
- Authority
- CA
- Canada
- Prior art keywords
- cross
- cellulose derivative
- entacapone
- composition
- linked cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative. The composition is premised on the discovery that the cross-linked cellulose derivative increases the release rate of entacapone or nitecapone from an oral compacte d composition. Preferably the amount of the cross-linked cellulose derivative in the composition is at least 6 % by weight, preferabl y from about 8 % to about 16 % weight, especially from about % to about 14 % by weight.
Description
PHARMACEUTICAL COMPOSITION COMPRISING ENTACAPONE OR NITECAPONE AS WELL AS A
CROSS-LINKED CELLULOSE DERIVATIVE
BACKGROUND OF THE INVENTION
The present invention relates to a new pharmaceutical composition comprising a catechol derivative and a cross-linked cellulose derivative as a dissolution enhancing agent. Accordingly, the present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative as a dissolution enhancing agent. Particularly, the invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative, wherein the amount of the cross-linked cellulose derivative in the composition is at least 6 /4 by weight, more preferably from about 8 % to about 16 % by weight, especially from about 10 % to 14 % by weight. Preferably the cross-linked cellulose derivative is cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof, and particularly croscarmellose sodium (i.e. cross-linked carboxymethylcellulose sodium, Ac-Di-Sol). Preferably the oral compacted composition is in the form of a tablet. Further, the present invention relates to a method of preparing an oral compacted composition comprising entacapone, nitecapone, or pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative. The present invention also relates to the use of a cross-GONFfRMATlON COPY
WO 00/15196 PCT/F199/00740 _ linked cellulose derivative in the manufacture of an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof.
The chemical names of entacapone and nitecapone are (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide and 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione, respectively. Entacapone and nitecapone are described in U.S. Patent No. 5,446,194 as catechol-O-methyltransferase (COMT) inhibitors. Enteral and parenteral routes of administration are discussed in U.S. Patent No. 5,446,194.
It is desirable that entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, is released from the oral composition as soon as possible after ingesting it. This can normally be achieved by using a dissolution enhancing agent in the pharmaceutical composition. The dissolution enhancing agent may be a disintegrant or any other agent that enhances the dissolution.
There is a vast selection of different dissolution enhancing agents, including disintegrants, on the market, which have different chemical and physical characteristics. When selecting the best dissolution enhancing agent to be used in a pharmaceutical composition in combination with an active agent, numerous factors have to be considered, e.g., the chemical and physical characteristics of the active agent and the dissolution enhancing agent, the chemical and physical characteristics of the auxiliary agents, such as diluents and binders, the method of preparing the composition, etc.
CROSS-LINKED CELLULOSE DERIVATIVE
BACKGROUND OF THE INVENTION
The present invention relates to a new pharmaceutical composition comprising a catechol derivative and a cross-linked cellulose derivative as a dissolution enhancing agent. Accordingly, the present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative as a dissolution enhancing agent. Particularly, the invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative, wherein the amount of the cross-linked cellulose derivative in the composition is at least 6 /4 by weight, more preferably from about 8 % to about 16 % by weight, especially from about 10 % to 14 % by weight. Preferably the cross-linked cellulose derivative is cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof, and particularly croscarmellose sodium (i.e. cross-linked carboxymethylcellulose sodium, Ac-Di-Sol). Preferably the oral compacted composition is in the form of a tablet. Further, the present invention relates to a method of preparing an oral compacted composition comprising entacapone, nitecapone, or pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative. The present invention also relates to the use of a cross-GONFfRMATlON COPY
WO 00/15196 PCT/F199/00740 _ linked cellulose derivative in the manufacture of an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof.
The chemical names of entacapone and nitecapone are (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide and 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione, respectively. Entacapone and nitecapone are described in U.S. Patent No. 5,446,194 as catechol-O-methyltransferase (COMT) inhibitors. Enteral and parenteral routes of administration are discussed in U.S. Patent No. 5,446,194.
It is desirable that entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, is released from the oral composition as soon as possible after ingesting it. This can normally be achieved by using a dissolution enhancing agent in the pharmaceutical composition. The dissolution enhancing agent may be a disintegrant or any other agent that enhances the dissolution.
There is a vast selection of different dissolution enhancing agents, including disintegrants, on the market, which have different chemical and physical characteristics. When selecting the best dissolution enhancing agent to be used in a pharmaceutical composition in combination with an active agent, numerous factors have to be considered, e.g., the chemical and physical characteristics of the active agent and the dissolution enhancing agent, the chemical and physical characteristics of the auxiliary agents, such as diluents and binders, the method of preparing the composition, etc.
WO 00/15196 PCT/F199/00740 _ A cross-linked cellulose derivative means unmodified or modified polymer of cellulose which is cross-linked in a manner generally known in the field of poylmer chemistry. Such cross-linked cellulose derivatives are well known as excipients in the field of pharmaceutical technology and as an example cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof can be mentioned. For instance croscarmellose sodium is a cross-linked polymer of carboxymethyl-cellulose sodium. According to the Handbook of Pharmaceutical Excipients (Ainley Wade and Paul J. Weller, Second Edition, The Pharmaceutical Press, London, 1994), it is used in oral pharmaceutical formulations as a disintegrant for tablets, capsules, and granules. Typically, concentrations from 0.5 to 5 % w/w are used as a tablet disintegrant.
Neither the above-cited patent nor any other patent or publication of which applicants are aware describes an oral compacted composition comprising entacapone, nitecapone, or pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative.
SUMMARY OF THE INVENTION
Applicants have discovered that a cross-linked cellulose derivative is a superior disintegrant to be used in an oral compacted composition comprising entacapone, nitecapone, or pharmaceutically acceptable salt thereof.
Accordingly, an object of the invention is to provide an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative. The composition is premised on the discovery that the cross-linked cellulose derivative essentially increases the release rate of entacapone or nitecapone from an oral compacted composition. Particularly, an object of the invention is to provide an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative, wherein the amount of the cross-linked cellulose derivative in the composition is at least 6 % by weight, more preferably from about 8 % to about 16 % by weight, especially from about 10% to 14 % by weight.
Preferably, the cross-linked cellulose derivative is cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof, more preferably croscarmellose sodium (Ac-Di-Sol). Preferably, the oral compacted composition is in the form of a tablet and, therefore, an object of the invention is to provide a tablet comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative.
A further object of the invention is to provide a tablet comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative, wherein the amount of the cross-linked cellulose derivative is at least 6 % by weight, more preferably from about 8 %
to about 16 % by weight, especially from about 10 % to about 14 % by weight.
An object of the invention is also to provide a method for preparing an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative, wherein said method comprises mixing a pharmaceutically effective amount of __ entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, one or more auxiliary agents, and a cross-linked cellulose derivative to obtain a first mixture; compacting and crushing the first mixture one or more times to obtain a plurality of granules; adding a lubricant, a glidant or a mixture thereof to the granules to obtain a second mixture; and compressing the second mixture into a plurality of tablets.
An object of the invention is to provide a method of inhibiting catechol-O-methyltransferase by administering to a patient in need thereof an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof.
A further aspect of the invention relates to the use of a cross-linked cellulose derivative in the manufacture of an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof.
Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
Neither the above-cited patent nor any other patent or publication of which applicants are aware describes an oral compacted composition comprising entacapone, nitecapone, or pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative.
SUMMARY OF THE INVENTION
Applicants have discovered that a cross-linked cellulose derivative is a superior disintegrant to be used in an oral compacted composition comprising entacapone, nitecapone, or pharmaceutically acceptable salt thereof.
Accordingly, an object of the invention is to provide an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative. The composition is premised on the discovery that the cross-linked cellulose derivative essentially increases the release rate of entacapone or nitecapone from an oral compacted composition. Particularly, an object of the invention is to provide an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative, wherein the amount of the cross-linked cellulose derivative in the composition is at least 6 % by weight, more preferably from about 8 % to about 16 % by weight, especially from about 10% to 14 % by weight.
Preferably, the cross-linked cellulose derivative is cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof, more preferably croscarmellose sodium (Ac-Di-Sol). Preferably, the oral compacted composition is in the form of a tablet and, therefore, an object of the invention is to provide a tablet comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative.
A further object of the invention is to provide a tablet comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative, wherein the amount of the cross-linked cellulose derivative is at least 6 % by weight, more preferably from about 8 %
to about 16 % by weight, especially from about 10 % to about 14 % by weight.
An object of the invention is also to provide a method for preparing an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, and a cross-linked cellulose derivative, wherein said method comprises mixing a pharmaceutically effective amount of __ entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, one or more auxiliary agents, and a cross-linked cellulose derivative to obtain a first mixture; compacting and crushing the first mixture one or more times to obtain a plurality of granules; adding a lubricant, a glidant or a mixture thereof to the granules to obtain a second mixture; and compressing the second mixture into a plurality of tablets.
An object of the invention is to provide a method of inhibiting catechol-O-methyltransferase by administering to a patient in need thereof an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof.
A further aspect of the invention relates to the use of a cross-linked cellulose derivative in the manufacture of an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof.
Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the effect of different dissolution enhancing agents on the dissolution of compacted entacapone 200 mg tablet formulations.
Figure 2 shows the effect of croscarmellose sodium on the dissolution of compacted entacapone 200 mg tablet formulations.
DETAILED DESCRIPTION OF THE INVENTION
Applicants have surprisingly discovered that the cross-linked cellulose derivative is effective for increasing the disintegration rate of an oral compacted composition comprising entacapone, nitecapone or a pharmaceutically acceptable salt thereof.
An oral compacted composition is a composition wherein a mixture of an active agent, one or more auxiliary agents and a dissolution enhancing agent is first compacted, then crushed into granules, and further the granules are tabletted or enclosed in a capsule. The best dissolution enhancing agent is the one that releases the active agent from the composition as fast as possible.
Applicants found that when compacting nitecapone, entacapone or a pharmaceutically acceptable salt thereof together with dissolution enhancing agents to an oral compacted composition, the cross-linked cellulose derivative is unexpectedly more efficient in releasing entacapone, nitecapone or a pharmaceutically acceptable salt thereof from the compacted composition than other common dissolution improving agents, such as starch, pregelatinized starch, micro-crystalline cellulose, mannitol, sodium starch glycolate, or sodium lauryl sulphate. The dissolution test of Example 1 shows that 90.1 % of entacapone is dissolved from a tablet comprising croscarmellose sodium as a disintegrant in 5 minutes (see Figure 1). This result is far superior when compared to 69.3 %, 55.4 %, 41.3 %, and 8.4 % for sodium lauryl sulphate, sodium starch glycolate, pregelatinized starch, and mannitol containing tablets, respectively.
Moreover, with the cross-linked cellulose derivative it is possible to compact nitecapone, entacapone or a salt thereof to a formulation which is both small in size (which is highly desirable in the treatment of certain conditions, e.g.
in the treatment of Parkinson's disease) and also superior in releasing nitecapone or entacapone or a salt thereof.
The cross-linked cellulose derivative is in the oral compacted composition in an amount to enhance the dissolution of the active agent. Applicants have surprisingly discovered that the best dissolution results for the oral compacted compositions of the invention are achieved when the amount of the cross-linked cellulose derivative is far more than what is suggested in the art.
Accordingly, it has been found that the amount of the cross-linked cellulose derivative in the oral compacted composition is preferably at least 6 % by weight. More preferably, the amount of the cross-linked cellulose derivative is from about 8 %
to about 16 % by weight, especially from about 10 % to 14 % by weight.
The amount of entacapone, nitecapone or a pharmaceutically acceptable salt thereof in the oral compacted composition is dependent on numerous factors known to one skilled in the art, such as, the type of mammal, the condition to be treated, the desired duration of use, etc. The compacted composition of the invention may also contain one or more other pharmaceutically active agents.
The amount of entacapone in a tablet according to the invention can be about 5-400 mg, preferably about 100-200 mg, more preferably 200 mg.
Entacapone and nitecapone can be prepared, for example, as described in U.S. Patent No. 5,446,194.
An oral compacted composition according to the invention can be prepared by mixing a pharmaceutically effective amount of entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, one or more auxiliary agents and a cross-linked cellulose derivative and further compacting and crushing the mixture to form granules. The compacting and crushing can be proceeded one or more times. The granules are then mixed with a lubricant, a glidant or a mixture thereof and the mixture is compressed into tablets. The tablets may be coated after tabletting. The granules may also be encapsulated to form capsules. The auxiliary agent may be a diluent, a binder or a mixture of different diluents and/or binders. Preferably at least one of the auxiliary agents is water soluble. Suitable diluents and binders include, e.g., microcrystalline cellulose, hypromellose (HPMC), povidone, starch, lactose, sucrose, mannitol, sorbitol, etc. Suitable lubricants and glidants include, e.g., magnesium stearate, calcium stearate, hydrogenated vegetable oil, talc, colloidal silicon dioxide, etc.
One skilled in the art would recognize other suitable auxiliary agents, lubricants and glidants that can be used in the composition of the present invention.
Figure 1 shows the effect of different dissolution enhancing agents on the dissolution of compacted entacapone 200 mg tablet formulations.
Figure 2 shows the effect of croscarmellose sodium on the dissolution of compacted entacapone 200 mg tablet formulations.
DETAILED DESCRIPTION OF THE INVENTION
Applicants have surprisingly discovered that the cross-linked cellulose derivative is effective for increasing the disintegration rate of an oral compacted composition comprising entacapone, nitecapone or a pharmaceutically acceptable salt thereof.
An oral compacted composition is a composition wherein a mixture of an active agent, one or more auxiliary agents and a dissolution enhancing agent is first compacted, then crushed into granules, and further the granules are tabletted or enclosed in a capsule. The best dissolution enhancing agent is the one that releases the active agent from the composition as fast as possible.
Applicants found that when compacting nitecapone, entacapone or a pharmaceutically acceptable salt thereof together with dissolution enhancing agents to an oral compacted composition, the cross-linked cellulose derivative is unexpectedly more efficient in releasing entacapone, nitecapone or a pharmaceutically acceptable salt thereof from the compacted composition than other common dissolution improving agents, such as starch, pregelatinized starch, micro-crystalline cellulose, mannitol, sodium starch glycolate, or sodium lauryl sulphate. The dissolution test of Example 1 shows that 90.1 % of entacapone is dissolved from a tablet comprising croscarmellose sodium as a disintegrant in 5 minutes (see Figure 1). This result is far superior when compared to 69.3 %, 55.4 %, 41.3 %, and 8.4 % for sodium lauryl sulphate, sodium starch glycolate, pregelatinized starch, and mannitol containing tablets, respectively.
Moreover, with the cross-linked cellulose derivative it is possible to compact nitecapone, entacapone or a salt thereof to a formulation which is both small in size (which is highly desirable in the treatment of certain conditions, e.g.
in the treatment of Parkinson's disease) and also superior in releasing nitecapone or entacapone or a salt thereof.
The cross-linked cellulose derivative is in the oral compacted composition in an amount to enhance the dissolution of the active agent. Applicants have surprisingly discovered that the best dissolution results for the oral compacted compositions of the invention are achieved when the amount of the cross-linked cellulose derivative is far more than what is suggested in the art.
Accordingly, it has been found that the amount of the cross-linked cellulose derivative in the oral compacted composition is preferably at least 6 % by weight. More preferably, the amount of the cross-linked cellulose derivative is from about 8 %
to about 16 % by weight, especially from about 10 % to 14 % by weight.
The amount of entacapone, nitecapone or a pharmaceutically acceptable salt thereof in the oral compacted composition is dependent on numerous factors known to one skilled in the art, such as, the type of mammal, the condition to be treated, the desired duration of use, etc. The compacted composition of the invention may also contain one or more other pharmaceutically active agents.
The amount of entacapone in a tablet according to the invention can be about 5-400 mg, preferably about 100-200 mg, more preferably 200 mg.
Entacapone and nitecapone can be prepared, for example, as described in U.S. Patent No. 5,446,194.
An oral compacted composition according to the invention can be prepared by mixing a pharmaceutically effective amount of entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, one or more auxiliary agents and a cross-linked cellulose derivative and further compacting and crushing the mixture to form granules. The compacting and crushing can be proceeded one or more times. The granules are then mixed with a lubricant, a glidant or a mixture thereof and the mixture is compressed into tablets. The tablets may be coated after tabletting. The granules may also be encapsulated to form capsules. The auxiliary agent may be a diluent, a binder or a mixture of different diluents and/or binders. Preferably at least one of the auxiliary agents is water soluble. Suitable diluents and binders include, e.g., microcrystalline cellulose, hypromellose (HPMC), povidone, starch, lactose, sucrose, mannitol, sorbitol, etc. Suitable lubricants and glidants include, e.g., magnesium stearate, calcium stearate, hydrogenated vegetable oil, talc, colloidal silicon dioxide, etc.
One skilled in the art would recognize other suitable auxiliary agents, lubricants and glidants that can be used in the composition of the present invention.
The invention will be further clarified by the following examples, which are intended to be purely exemplary of the invention.
The dissolution of entacapone 200 mg tablet formulations containing different disintegrants were tested. The tablets were prepared by mixing, compacting, crushing and compressing as described above. The formulations were as described in Table 1. The dissolution of each formulation was tested using the basket method with a 100 rpm speed and 900 ml medium of phosphate buffer pH 5.8.
The amount of entacapone released was determined by a spectrophotometric method using a UVNIS spectrophotometer. The detection wavelength was 313 nm. The results, which are presented in Figure 1, show that the formulation containg croscarmellose sodium (Formul. 5) releases entacapone fastest.
The dissolution of entacapone 200 mg tablet formulations containing different disintegrants were tested. The tablets were prepared by mixing, compacting, crushing and compressing as described above. The formulations were as described in Table 1. The dissolution of each formulation was tested using the basket method with a 100 rpm speed and 900 ml medium of phosphate buffer pH 5.8.
The amount of entacapone released was determined by a spectrophotometric method using a UVNIS spectrophotometer. The detection wavelength was 313 nm. The results, which are presented in Figure 1, show that the formulation containg croscarmellose sodium (Formul. 5) releases entacapone fastest.
Entacapone 200 mg tablet formulations containing different dissolution enhancing agents used in the dissolution test.
Compound Formul.1 Formul. 2 Formul. 3 Formul. 4 Formul. 5 (mg) (mg) (mg) (mg) (mg) Entacapone 200 200 200 200 200 Microcryst.cellulose 50 210 410 420 370 Mannitol 400 0 0 0 0 Pregelatinized Starch 0 180 0 0 0 Sodium Starch 0 0 40 0 0 Glycolate Sodium Lauryl 0 0 0 30 0 Sulphate Croscarmellose 0 0 0 0 80 Sodium Magnesium Stearate 10 10 10 10 10 The effect of croscarmellose sodium on the dissolution of compacted entacapone 200 tablet formulations was tested according to the method described in Example 1. The different formulations, i.e., Formul. 6-Formul.
Compound Formul.1 Formul. 2 Formul. 3 Formul. 4 Formul. 5 (mg) (mg) (mg) (mg) (mg) Entacapone 200 200 200 200 200 Microcryst.cellulose 50 210 410 420 370 Mannitol 400 0 0 0 0 Pregelatinized Starch 0 180 0 0 0 Sodium Starch 0 0 40 0 0 Glycolate Sodium Lauryl 0 0 0 30 0 Sulphate Croscarmellose 0 0 0 0 80 Sodium Magnesium Stearate 10 10 10 10 10 The effect of croscarmellose sodium on the dissolution of compacted entacapone 200 tablet formulations was tested according to the method described in Example 1. The different formulations, i.e., Formul. 6-Formul.
10, are described in Table 2. The results of the dissolution test are shown in Figure 2. The formulation containing the most croscarmellose sodium (100 mg) released entacapone the fastest.
Compacted entacapone 200 mg tablet formulations containing different amounts of croscarmellose sodium.
Compound Formul. 6 Formul. 7 Formul. 8 Formul. 9 Formu1.10 (mg) (mg) (mg) (mg) (mg) Entacapone 200 200 200 200 200 Microcryst. cellulose 445 405 220 200 180 Mannitol 0 0 170 170 170 Croscarmellose Sodium 0 40 60 80 100 Magnesium Stearate 15 15 12 12 12 Oral compact compositions according to the invention comprising entacapone as an active agent can include for instance those described in Table 3.
Compacted entacapone 200 mg tablet formulations containing different amounts of croscarmellose sodium.
Compound Formul. 6 Formul. 7 Formul. 8 Formul. 9 Formu1.10 (mg) (mg) (mg) (mg) (mg) Entacapone 200 200 200 200 200 Microcryst. cellulose 445 405 220 200 180 Mannitol 0 0 170 170 170 Croscarmellose Sodium 0 40 60 80 100 Magnesium Stearate 15 15 12 12 12 Oral compact compositions according to the invention comprising entacapone as an active agent can include for instance those described in Table 3.
Different oral compacted entacapone 200 mg tablet formulations.
Compound Formul. 11 Formul. 12 Formul. 13 Formul. 14 Formul.15 (mg) (mg) (mg) (mg) (mg) Entacapone 200 200 200 200 200 Microcrystalline cellulose 290 230 160 190 120 Sucrose 10 0 100 60 190 Mannitol 90 160 80 140 50 Hypromellose (HPMC) 5 0 20 0 10 Croscarmellose Sodium 73 80 82 82 88 Hydrogenated vegetable oil 0 5 38 2 14 Magnesium Stearate 15 8 3 9 11 Those skilled in the art will recognize that while specific embodiments have been illustrated and described, various modifications and changes may be made without departing from the spirit and scope of the invention.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
The references discussed herein are specifically incorporated by reference in their entirety.
Compound Formul. 11 Formul. 12 Formul. 13 Formul. 14 Formul.15 (mg) (mg) (mg) (mg) (mg) Entacapone 200 200 200 200 200 Microcrystalline cellulose 290 230 160 190 120 Sucrose 10 0 100 60 190 Mannitol 90 160 80 140 50 Hypromellose (HPMC) 5 0 20 0 10 Croscarmellose Sodium 73 80 82 82 88 Hydrogenated vegetable oil 0 5 38 2 14 Magnesium Stearate 15 8 3 9 11 Those skilled in the art will recognize that while specific embodiments have been illustrated and described, various modifications and changes may be made without departing from the spirit and scope of the invention.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
The references discussed herein are specifically incorporated by reference in their entirety.
Claims (17)
1. An oral compacted composition comprising a pharmaceutically effective amount of entacapone, nitecapone or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative.
2. The composition according to claim 1, comprising entacapone or a pharmaceutically acceptable salt thereof and a cross-linked cellulose derivative.
3. The composition according to claim 1, wherein the amount of the cross-linked cellulose derivative in the composition is at least 6 % by weight.
4. The composition according to claim 3, wherein the amount of the cross-linked cellulose derivative in the composition is from about 8 % to about 16 % by weight.
5. The composition according to claim 4, wherein the amount of the cross-linked cellulose derivative in the composition is from about 10 % to about 14 % by weight.
6. The composition according to any one of claims 1 to 5, wherein the cross-linked cellulose derivative is cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof.
7. The composition according to any one of claims 1 to 6, wherein the cross-linked cellulose derivative is croscarmellose sodium.
8. The composition according to claim 1, wherein the composition is in the form of a tablet.
9. The composition according to claim 2, wherein the amount of entacapone is from about 5 mg to about 400 mg.
10. A method for preparing an oral compacted composition comprising entacapone, nitecapone or a pharmaceutically acceptable salt thereof, wherein the method comprises a) mixing a pharmaceutically effective amount of entacapone, nitecapone, or a pharmaceutically acceptable salt thereof, one or more auxiliary agents and a cross-linked cellulose derivative to obtain a first mixture;
b) compacting and crushing the first mixture one or more times to obtain a plurality of granules;
c) adding a lubricant, a glidant, or a mixture thereof to the granules to obtain a second mixture; and d) compressing the second mixture into a plurality of tablets.
b) compacting and crushing the first mixture one or more times to obtain a plurality of granules;
c) adding a lubricant, a glidant, or a mixture thereof to the granules to obtain a second mixture; and d) compressing the second mixture into a plurality of tablets.
11. The method according to claim 10, wherein the amount of the cross-linked cellulose derivative in the composition is at least 6 % by weight.
12. The method according to claim 11, wherein the amount of the cross-linked cellulose derivative in the composition is from about 8 % to about 16 % by weight.
13. The method according to claim 12, wherein the amount of the cross-linked cellulose derivative in the composition is from about 10 % to about 14 % by weight.
14. The method according to claim 10, wherein at least one of the auxiliary agents is water soluble.
15. The method according to claim 13, wherein the amount of entacapone is from about 5 to about 400 mg.
16. The method according to any one of claims 10 to 15, wherein the cross-linked cellulose derivative is cross-linked carboxymethylcellulose or a pharmaceutically acceptable salt thereof.
17. The method according to any one of claims 10 to 16, wherein the cross-linked cellulose derivative is croscarmellose sodium.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/152,263 US6599530B2 (en) | 1998-09-14 | 1998-09-14 | Oral compacted composition comprising catechol derivatives |
| US09/152,263 | 1998-09-14 | ||
| PCT/FI1999/000740 WO2000015196A1 (en) | 1998-09-14 | 1999-09-13 | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2342634A1 CA2342634A1 (en) | 2000-03-23 |
| CA2342634C true CA2342634C (en) | 2008-01-29 |
Family
ID=22542186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002342634A Expired - Lifetime CA2342634C (en) | 1998-09-14 | 1999-09-13 | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6599530B2 (en) |
| EP (1) | EP1112065B1 (en) |
| JP (1) | JP4619537B2 (en) |
| KR (1) | KR100732187B1 (en) |
| CN (1) | CN1151778C (en) |
| AR (1) | AR021806A1 (en) |
| AT (1) | ATE256454T1 (en) |
| AU (1) | AU746889B2 (en) |
| BG (1) | BG65041B1 (en) |
| BR (1) | BR9913681A (en) |
| CA (1) | CA2342634C (en) |
| CO (1) | CO5130008A1 (en) |
| CZ (1) | CZ293960B6 (en) |
| DE (1) | DE69913714T2 (en) |
| DK (1) | DK1112065T3 (en) |
| EA (1) | EA003282B1 (en) |
| EE (1) | EE04657B1 (en) |
| ES (1) | ES2213381T3 (en) |
| GE (1) | GEP20033062B (en) |
| HK (1) | HK1039750B (en) |
| HR (1) | HRP20010277B1 (en) |
| HU (1) | HU228910B1 (en) |
| ID (1) | ID29026A (en) |
| IL (1) | IL141681A0 (en) |
| ME (1) | ME00706B (en) |
| MY (1) | MY124394A (en) |
| NO (1) | NO331641B1 (en) |
| NZ (1) | NZ510583A (en) |
| PE (1) | PE20001060A1 (en) |
| PL (1) | PL193454B1 (en) |
| PT (1) | PT1112065E (en) |
| RS (1) | RS49723B (en) |
| SI (1) | SI1112065T1 (en) |
| SK (1) | SK284049B6 (en) |
| TR (1) | TR200100752T2 (en) |
| TW (1) | TWI222367B (en) |
| UA (1) | UA73925C2 (en) |
| WO (1) | WO2000015196A1 (en) |
| ZA (1) | ZA200102084B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI109453B (en) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Pharmaceutical composition |
| FI20000635A0 (en) * | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | Use of COMT inhibitors as an analgesic |
| US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| CN101184483B (en) * | 2005-06-08 | 2011-08-10 | 奥赖恩公司 | An entacapone-containging oral dosage form |
| AU2012216377C1 (en) * | 2005-06-08 | 2013-10-10 | Orion Corporation | Oral dosage form |
| US8772346B2 (en) | 2005-11-09 | 2014-07-08 | Torrent Pharmaceuticals Limited | Pharmaceutical composition |
| JP2009527504A (en) * | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | Compositions and methods for induction and maintenance of good quality sleep |
| GB2429645A (en) * | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| WO2007113371A1 (en) * | 2006-03-31 | 2007-10-11 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| CA2572004A1 (en) * | 2006-12-08 | 2008-06-08 | Bernard Charles Sherman | Tablets comprising entacapone and crospovidone |
| EP1946756A1 (en) * | 2007-01-17 | 2008-07-23 | Revotar Biopharmaceuticals AG | Use of entacapone in cosmetic, dermatological and pharmaceutical compositions |
| CN101939002B (en) * | 2008-02-06 | 2012-12-26 | 沃克哈特研究中心 | Pharmaceutical compositions of entacapone co-micronized with sugar alcohols |
| EP2252284B1 (en) * | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| NZ591326A (en) * | 2008-08-22 | 2012-12-21 | Wockhardt Research Center | An extended release pharmaceutical composition of entacapone or salts thereof |
| CN102781440B (en) * | 2009-12-25 | 2015-06-17 | 因华生技制药股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method thereof |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| WO2012145893A1 (en) * | 2011-04-26 | 2012-11-01 | 因华生技制药股份有限公司 | A composition of entacopone |
| RU2017120184A (en) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | DRUGS TO DELAY THE COURSE OF PARKINSON'S DISEASE |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| CN106236720A (en) * | 2016-08-29 | 2016-12-21 | 海南通用康力制药有限公司 | A kind of pharmaceutical composition of entacapone and preparation method thereof |
| CN113274362A (en) * | 2021-03-31 | 2021-08-20 | 海南通用康力制药有限公司 | Method for producing entacapone tablets |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005804A1 (en) * | 1986-04-01 | 1987-10-08 | The Upjohn Company | Methylprednisolone/sodium carboxymethyl starch tablet composition |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| US5489614A (en) * | 1987-11-27 | 1996-02-06 | Orion-Yhtyma Oy | Catechol derivatives, their physiologically acceptable salts, esters and use |
| US5380535A (en) * | 1991-05-28 | 1995-01-10 | Geyer; Robert P. | Chewable drug-delivery compositions and methods for preparing the same |
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
-
1998
- 1998-09-14 US US09/152,263 patent/US6599530B2/en not_active Expired - Lifetime
-
1999
- 1999-09-01 TW TW088115016A patent/TWI222367B/en not_active IP Right Cessation
- 1999-09-06 MY MYPI99003853A patent/MY124394A/en unknown
- 1999-09-09 PE PE1999000912A patent/PE20001060A1/en not_active IP Right Cessation
- 1999-09-13 EA EA200100354A patent/EA003282B1/en not_active IP Right Cessation
- 1999-09-13 ID IDW20010795A patent/ID29026A/en unknown
- 1999-09-13 WO PCT/FI1999/000740 patent/WO2000015196A1/en active IP Right Grant
- 1999-09-13 RS YUP-193/01A patent/RS49723B/en unknown
- 1999-09-13 SI SI9930508T patent/SI1112065T1/en unknown
- 1999-09-13 CO CO99057858A patent/CO5130008A1/en unknown
- 1999-09-13 BR BR9913681-3A patent/BR9913681A/en not_active Application Discontinuation
- 1999-09-13 DE DE69913714T patent/DE69913714T2/en not_active Expired - Lifetime
- 1999-09-13 CN CNB998109134A patent/CN1151778C/en not_active Expired - Lifetime
- 1999-09-13 KR KR1020017003245A patent/KR100732187B1/en active IP Right Grant
- 1999-09-13 GE GEAP19995853A patent/GEP20033062B/en unknown
- 1999-09-13 IL IL14168199A patent/IL141681A0/en not_active IP Right Cessation
- 1999-09-13 ES ES99944655T patent/ES2213381T3/en not_active Expired - Lifetime
- 1999-09-13 CZ CZ2001792A patent/CZ293960B6/en not_active IP Right Cessation
- 1999-09-13 PT PT99944655T patent/PT1112065E/en unknown
- 1999-09-13 NZ NZ510583A patent/NZ510583A/en not_active IP Right Cessation
- 1999-09-13 ME MEP-2001-193A patent/ME00706B/en unknown
- 1999-09-13 CA CA002342634A patent/CA2342634C/en not_active Expired - Lifetime
- 1999-09-13 JP JP2000569780A patent/JP4619537B2/en not_active Expired - Lifetime
- 1999-09-13 AT AT99944655T patent/ATE256454T1/en active
- 1999-09-13 PL PL99346618A patent/PL193454B1/en unknown
- 1999-09-13 AU AU57482/99A patent/AU746889B2/en not_active Expired
- 1999-09-13 SK SK307-2001A patent/SK284049B6/en not_active IP Right Cessation
- 1999-09-13 DK DK99944655T patent/DK1112065T3/en active
- 1999-09-13 TR TR2001/00752T patent/TR200100752T2/en unknown
- 1999-09-13 EE EEP200100147A patent/EE04657B1/en unknown
- 1999-09-13 EP EP99944655A patent/EP1112065B1/en not_active Expired - Lifetime
- 1999-09-13 UA UA2001042521A patent/UA73925C2/en unknown
- 1999-09-13 HU HU0103454A patent/HU228910B1/en unknown
- 1999-09-14 AR ARP990104612A patent/AR021806A1/en active IP Right Grant
-
2001
- 2001-03-13 NO NO20011278A patent/NO331641B1/en not_active IP Right Cessation
- 2001-03-13 ZA ZA200102084A patent/ZA200102084B/en unknown
- 2001-04-11 BG BG105436A patent/BG65041B1/en unknown
- 2001-04-12 HR HR20010277A patent/HRP20010277B1/en not_active IP Right Cessation
-
2002
- 2002-02-22 HK HK02101311.8A patent/HK1039750B/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2342634C (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| AU2002301845B2 (en) | Modified release tamsulosin tablets | |
| TWI260221B (en) | 5HT4 partial agonist pharmaceutical compositions | |
| CA2000763C (en) | Dispersable formulation | |
| CA2611114A1 (en) | An entacapone-containing oral dosage form | |
| AU7228500A (en) | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route | |
| US6150410A (en) | pH independent extended release pharmaceutical formulation | |
| WO2005089720A1 (en) | Valsartan tablets and the process for the preparation thereof | |
| JPH0757726B2 (en) | Sustained release tablets based on high molecular weight hydroxypropyl methylcellulose | |
| EP1146864B1 (en) | Ph independent extended release pharmaceutical formulation | |
| NZ207768A (en) | Sustained release tablets comprising dipyridamole | |
| EP0975337B1 (en) | Fast release compressed tablet of flurbiprofen | |
| MXPA01002650A (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| CA2239931A1 (en) | Pharmaceutical tablet comprising norfloxacin | |
| CA2343949A1 (en) | Benazepril hydrochloride tablet formulations | |
| US20030229101A1 (en) | Tablets comprising ciprofloxacin hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |